---
trial_id: 821
discovery_date: 2022-05-15 20:21:08.589750
date: 2022-05-15 20:21:08.589750
title: "A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and..."
summary: |
  <p>EudraCT Number: 2015-005431-41<br />Sponsor Protocol Number: BN40900(SA-309JG)<br />Sponsor Name: F. Hoffmann-La Roche Ltd.<br />Start Date: 2017-10-16<br />Medical condition: Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD)<br />Disease: <br />Version: 20.0<br />SOC Term: 100000004852<br />Classification Code: 10029322<br />Term: Neuromyelitis optica<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005431-41/PL">PL</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005431-41/HR">HR</a> (Completed)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005431-41'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2015-005431-41<br />Sponsor Protocol Number: BN40900(SA-309JG)<br />Sponsor Name: F. Hoffmann-La Roche Ltd.<br />Start Date: 2017-10-16<br />Medical condition: Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD)<br />Disease: <br />Version: 20.0<br />SOC Term: 100000004852<br />Classification Code: 10029322<br />Term: Neuromyelitis optica<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005431-41/PL">PL</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005431-41/HR">HR</a> (Completed)</p>